daclizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4953	152923-56-3

Description:

Molecule	Description
Synonyms: zinbryta daclizumab zenapax	An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

zinbryta
daclizumab
zenapax

An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
5	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 10, 1997	FDA	HOFFMAN-LA ROCHE
Feb. 26, 1999	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2432.68	47.43	405	4584	4467	63479566
Transplant rejection	1931.24	47.43	376	4613	10404	63473629
Ovarian cyst	1715.25	47.43	364	4625	15581	63468452
Acne	1593.95	47.43	367	4622	22926	63461107
Alopecia	777.00	47.43	418	4571	337118	63146915
Liver function test abnormal	411.56	47.43	151	4838	48030	63436003
Sleep disorder due to general medical condition, insomnia type	374.44	47.43	144	4845	52073	63431960
Multiple sclerosis relapse	281.92	47.43	115	4874	48363	63435670
Rheumatoid arthritis	180.47	47.43	153	4836	253666	63230367
Pneumonia	141.72	47.43	176	4813	456591	63027442

Showing 1 to 10 of 17 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	148.33	37.54	36	558	13097	34943240

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2373.37	43.52	408	4736	6813	79732431
Ovarian cyst	1876.56	43.52	365	4779	12290	79726954
Transplant rejection	1766.41	43.52	373	4771	19064	79720180
Acne	1609.11	43.52	367	4777	26823	79712421
Alopecia	999.37	43.52	416	4728	230939	79508305
Sleep disorder due to general medical condition, insomnia type	427.66	43.52	144	5000	43412	79695832
Liver function test abnormal	401.29	43.52	152	4992	64323	79674921
Multiple sclerosis relapse	319.54	43.52	118	5026	46415	79692829
Rheumatoid arthritis	231.95	43.52	152	4992	208318	79530926
Condition aggravated	124.98	43.52	157	4987	500967	79238277

Showing 1 to 10 of 18 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L04AC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA EPC	N0000175622	Interleukin-2 Receptor Blocking Antibody
FDA MoA	N0000010279	Interleukin 2 Receptor Antagonists
FDA MoA	N0000175621	Interleukin 2 Receptor-directed Antibody Interactions
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents